Gadoversetamide

CHEMBL1200457 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
661.8 g/mol
LogP
Phase
4

This gadolinium-based contrast agent is used to enhance MRI images of the brain and spine, helping to detect tumors, inflammation, and other abnormalities. Like other gadolinium agents, it shortens tissue relaxation times to produce brighter images in areas of interest.

Masse moléculaire

661,8000 g/mol

TPSA

207,00 Ų

Mécanisme d'action

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COCCNC(=O)CN(CCN(CCN(CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3]

InChI

InChI=1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);/q;+3/p-3

Molecular Formula

C20H34GdN5O10

HBD / HBA

2 / 13

Liaisons Rotatives

19

Atomes Lourds

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This gadolinium-based contrast agent is used to enhance MRI images of the brain and spine, helping to detect tumors, inflammation, and other abnormalities. Like other gadolinium agents, it shortens tissue relaxation times to produce brighter images in areas of interest.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Gadoversetamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200457. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 444013. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.